» Articles » PMID: 12611451

Estradiol Promotes Growth and Angiogenesis in Polyoma Middle T Transgenic Mouse Mammary Tumor Explants

Overview
Specialty Oncology
Date 2003 Mar 4
PMID 12611451
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Estrogen is important for breast carcinogenesis and the majority of breast cancers maintain hormone dependency. Estrogen has the ability to stimulate both breast epithelial cell growth and angiogenesis, and a well-characterized in vivo cancer model where these functional interactions can be studied is lacking. We demonstrate estrogen dependent angiogenesis, growth in vivo, and proliferation in vitro, in explants from polyoma middle T transgenic mouse mammary tumors. Thus, in addition to genetic similarities, this model also exerts a sex hormone, and angiogenic phenotype similar to human breast cancer. This immune-competent animal model offers the opportunity to study molecular events in estrogen dependent breast cancer.

Citing Articles

Elucidating Sex-Specific Immune Profiles in a Breast Cancer Model.

Hargrove-Wiley E, Obodo D, Bindeman W, Fingleton B Int J Mol Sci. 2024; 25(23).

PMID: 39684829 PMC: 11641823. DOI: 10.3390/ijms252313113.


Rat Models of Hormone Receptor-Positive Breast Cancer.

Nicotra R, Lutz C, Messal H, Jonkers J J Mammary Gland Biol Neoplasia. 2024; 29(1):12.

PMID: 38913216 PMC: 11196369. DOI: 10.1007/s10911-024-09566-0.


Insights from transgenic mouse models of PyMT-induced breast cancer: recapitulating human breast cancer progression in vivo.

Attalla S, Taifour T, Bui T, Muller W Oncogene. 2020; 40(3):475-491.

PMID: 33235291 PMC: 7819848. DOI: 10.1038/s41388-020-01560-0.


Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.

Mishra A, Abrahamsson A, Dabrosin C Oncotarget. 2016; 7(35):56876-56888.

PMID: 27486755 PMC: 5302959. DOI: 10.18632/oncotarget.10871.


Personalized in vitro cancer models to predict therapeutic response: Challenges and a framework for improvement.

Morgan M, Johnson B, Livingston M, Schuler L, Alarid E, Sung K Pharmacol Ther. 2016; 165:79-92.

PMID: 27218886 PMC: 5439438. DOI: 10.1016/j.pharmthera.2016.05.007.